These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16985049)

  • 1. Gene therapy with TRAIL against renal cell carcinoma.
    Matsubara H; Mizutani Y; Hongo F; Nakanishi H; Kimura Y; Ushijima S; Kawauchi A; Tamura T; Sakata T; Miki T
    Mol Cancer Ther; 2006 Sep; 5(9):2165-71. PubMed ID: 16985049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil.
    Mizutani Y; Nakanishi H; Yoshida O; Fukushima M; Bonavida B; Miki T
    Eur J Cancer; 2002 Jan; 38(1):167-76. PubMed ID: 11750847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant induction of apoptosis in renal cell carcinoma cells transfected with cationic multilamellar liposomes containing the human interferon-β gene through activation of the intracellular type 1 interferon signal pathway.
    Takaha N; Nakanishi H; Kimura Y; Hongo F; Kamoi K; Kawauchi A; Mizuno M; Yoshida J; Wakabayashi T; Miki T
    Int J Oncol; 2012 May; 40(5):1441-6. PubMed ID: 22344395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant antitumoral activity of cationic multilamellar liposomes containing human IFN-beta gene against human renal cell carcinoma.
    Nakanishi H; Mizutani Y; Kawauchi A; Ukimura O; Shiraishi T; Hatano M; Mizuno M; Yoshida J; Miki T
    Clin Cancer Res; 2003 Mar; 9(3):1129-35. PubMed ID: 12631618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma.
    Yamamoto K; Mizutani Y; Nakanishi H; Fujiwara J; Ishida H; Toiyama D; Abe K; Hayashi I; Okada K; Kawauchi A; Mizuno M; Yoshida J; Miki T
    Int J Oncol; 2008 Sep; 33(3):565-71. PubMed ID: 18695887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
    VanOosten RL; Earel JK; Griffith TS
    Cancer Gene Ther; 2006 Jun; 13(6):628-32. PubMed ID: 16456549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo.
    Zeng Y; Wu XX; Fiscella M; Shimada O; Humphreys R; Albert V; Kakehi Y
    Int J Oncol; 2006 Feb; 28(2):421-30. PubMed ID: 16391797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Itashiki Y; Harada K; Ferdous T; Yoshida H
    Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electroporation-mediated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L gene therapy for hepatocellular carcinoma.
    Yamashita Y; Shimada M; Tanaka S; Okamamoto M; Miyazaki J; Sugimachi K
    Hum Gene Ther; 2002 Jan; 13(2):275-86. PubMed ID: 11812283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FTY720 enhances TRAIL-mediated apoptosis by up-regulating DR5 and down-regulating Mcl-1 in cancer cells.
    Woo SM; Seo BR; Min KJ; Kwon TK
    Oncotarget; 2015 May; 6(13):11614-26. PubMed ID: 25843953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy.
    Sourbier C; Lindner V; Lang H; Agouni A; Schordan E; Danilin S; Rothhut S; Jacqmin D; Helwig JJ; Massfelder T
    Cancer Res; 2006 May; 66(10):5130-42. PubMed ID: 16707436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy.
    Norian LA; Kresowik TP; Rosevear HM; James BR; Rosean TR; Lightfoot AJ; Kucaba TA; Schwarz C; Weydert CJ; Henry MD; Griffith TS
    PLoS One; 2012; 7(2):e31085. PubMed ID: 22312440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eupafolin enhances TRAIL-mediated apoptosis through cathepsin S-induced down-regulation of Mcl-1 expression and AMPK-mediated Bim up-regulation in renal carcinoma Caki cells.
    Han MA; Min KJ; Woo SM; Seo BR; Kwon TK
    Oncotarget; 2016 Oct; 7(40):65707-65720. PubMed ID: 27582546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
    Naka T; Sugamura K; Hylander BL; Widmer MB; Rustum YM; Repasky EA
    Cancer Res; 2002 Oct; 62(20):5800-6. PubMed ID: 12384541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer.
    Zhang Z; Huang Y; Newman K; Gu J; Zhang X; Wu H; Zhao M; Xianyu Z; Liu X
    Clin Cancer Res; 2009 Aug; 15(16):5154-60. PubMed ID: 19671855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
    Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
    J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Cathepsin S Induces Mitochondrial ROS That Sensitizes TRAIL-Mediated Apoptosis Through p53-Mediated Downregulation of Bcl-2 and c-FLIP.
    Seo BR; Min KJ; Woo SM; Choe M; Choi KS; Lee YK; Yoon G; Kwon TK
    Antioxid Redox Signal; 2017 Aug; 27(4):215-233. PubMed ID: 27927016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6-Shogaol enhances renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen species-mediated cytochrome c release and down-regulation of c-FLIP(L) expression.
    Han MA; Woo SM; Min KJ; Kim S; Park JW; Kim DE; Kim SH; Choi YH; Kwon TK
    Chem Biol Interact; 2015 Feb; 228():69-78. PubMed ID: 25619640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms.
    Yang L; Wang Y; Zheng H; Zhang D; Wu X; Sun G; Yang T
    J Chemother; 2017 Jun; 29(3):179-188. PubMed ID: 28067150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK.
    Kim SW; Kim SJ; Park SH; Yang HG; Kang MC; Choi YW; Kim SM; Jeun SS; Sung YC
    Clin Cancer Res; 2013 Jan; 19(2):415-27. PubMed ID: 23204131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.